Under surveillance.
D001709:Biotechnology / Q000639:trends*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib